Zurcher Kantonalbank Zurich Cantonalbank slash its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Ranking) by 14.9% in the course of the 1st quarter, according to its most new Sort 13F filing with the Securities and Trade Commission (SEC). The fund owned 8,912 shares of the specialty pharmaceutical company’s inventory right after marketing 1,557 shares throughout the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Supernus Pharmaceuticals have been truly worth $288,000 at the conclusion of the most recent quarter.
Various other big investors have also modified their holdings of the company. Stephens Financial commitment Management Team LLC boosted its situation in Supernus Prescription drugs by 27.2% through the fourth quarter. Stephens Financial commitment Administration Group LLC now owns 1,577,980 shares of the specialty pharmaceutical company’s inventory well worth $46,014,000 right after obtaining an supplemental 337,902 shares all through the past quarter. Lisanti Capital Development LLC obtained a new stake in Supernus Prescribed drugs during the fourth quarter worthy of around $8,878,000. GW&K Financial investment Management LLC boosted its place in Supernus Prescribed drugs by 13.% all through the fourth quarter. GW&K Financial investment Management LLC now owns 1,836,466 shares of the specialty pharmaceutical company’s inventory worthy of $53,551,000 right after getting an supplemental 210,976 shares throughout the past quarter. Congress Wealth Administration LLC DE obtained a new stake in Supernus Pharmaceuticals through the fourth quarter well worth somewhere around $3,319,000. Lastly, Congress Asset Administration Co. MA boosted its situation in Supernus Prescription drugs by 26.2% all through the fourth quarter. Congress Asset Administration Co. MA now owns 396,105 shares of the specialty pharmaceutical company’s stock worth $11,550,000 after attaining an supplemental 82,250 shares for the duration of the past quarter.
Supernus Prescription drugs Inventory Overall performance
NASDAQ:SUPN opened at $29.68 on Friday. The firm has a rapid ratio of 1.69, a current ratio of 2.00 and a personal debt-to-equity ratio of .48. The business has a sector cap of $1.59 billion, a P/E ratio of 22.83 and a beta of 1.03. Supernus Prescription drugs, Inc. has a fifty-two week small of $23.15 and a fifty-two week high of $34.50. The firm’s 50 working day relocating ordinary is $27.98 and its two-hundred working day shifting ordinary is $29.67.
Supernus Prescription drugs (NASDAQ:SUPN – Get Rating) previous issued its earnings success on Monday, Might 9th. The specialty pharmaceutical corporation documented $.43 EPS for the quarter, beating analysts’ consensus estimates of $.26 by $.17. Supernus Prescribed drugs experienced a net margin of 12.20% and a return on fairness of 9.05%. The organization experienced revenue of $152.50 million for the quarter, when compared to the consensus estimate of $150.47 million. For the duration of the exact quarter past year, the agency posted $.11 EPS. The business’s income for the quarter was up 16.5% when compared to the exact same quarter final yr. Analysts be expecting that Supernus Pharmaceuticals, Inc. will write-up 1.64 EPS for the existing yr.
Wall Road Analysts Forecast Expansion
A number of analysts not too long ago issued studies on SUPN shares. TheStreet reduced shares of Supernus Prescribed drugs from a “b-” score to a “c+” score in a research report on Monday, April 18th. StockNews.com elevated shares of Supernus Prescribed drugs from a “hold” rating to a “buy” score in a exploration take note on Monday, April 18th.
Supernus Prescription drugs Profile
Supernus Prescription drugs, Inc, a biopharmaceutical organization, focuses on the progress and commercialization of merchandise for the therapy of central nervous process (CNS) conditions in the United States. Its industrial items are Trokendi XR, an extended release topiramate solution indicated for the therapy of epilepsy, as very well as for the prophylaxis of migraine headache and Oxtellar XR, an prolonged launch oxcarbazepine for the monotherapy treatment method of partial onset epilepsy seizures in adults and small children between 6 to 17 many years of age.
More Looking at
Get News & Rankings for Supernus Prescription drugs Day by day – Enter your e-mail handle underneath to get a concise day by day summary of the hottest information and analysts’ ratings for Supernus Prescribed drugs and linked businesses with MarketBeat.com’s Absolutely free everyday e-mail newsletter.